马吲哚治疗单纯性肥胖的临床观察

A CLINICAL STUDY OF MAZINOOL ON SIMPLE OBESITY

单纯性肥胖１０８例采取随机、双盲分成两组各５４例。年龄、性别、体重程度无明显差别，有可比性。治疗组口服马吲跺１ｍｇ，２次／日，对照组口服芬氟拉明２０ｍｇ，３次／日；疗程８周。结果：治疗组体重平均下降５，１４±１．６５ｋｇ、总有效率１００％（有效、显效率８８．９％）；对照组为４．２８±１．４８及９２．６％（７２．２％）．两组均有降低血压、血清总胆固醇（ＴＣ）、甘油三酯（ＴＧ）、血糖、胰岛素、生长激素和升高超氧化物歧化酶－锌－铜作用。但治疗组对ＴＣ、ＴＧ、收缩压、舒张压、生长激素、胰岛素及口服葡萄糖耐量试验后胰岛素及血糖面积均优于对照组（Ｐ＜０．０１和Ｐ＜０．０５）。显示马吲哚抗胰岛素抵抗更优于芬氟拉明。此外，马吲哚有克服嗜睡、胃肠道副反应少的作用。马吲哚在减肥同时对冠心病防治更有利。

One hundred and four simple obese patients were divided into two groups by randomization and doubleblind,and given mazindoll mg twice daily or fenfluramine 20 mg three times daily (control)respectively for 8 weeks. There was no difference in age, sex,and body weight between the two groups. The results showed that average body weight loss and tatal effectual rate in the mazindol treated group were 5. 14 ± 1. 65 kg (p< 0. 01vs. control) and 100% (effectual rate 88. 9%), while those in the fenfluramine treated group were 4. 28 ±1. 48 kg and 92. 6% (72. 2%),respectively. Both of the drugs could decrease blood pressure,serum total cholesterol and triglyceride , blood glucose , plasma insulin and growth hormone; and increase serum SOD-Cu2+-Zn2+.However, better effects of decreasing systolic and diastolic blood pressure, total cholearerol, triglyceride,growth hormone, insulin, and also serum insulin and plasma glucose and their areas under the curve (AUC)after OGTT were found in the mazindol than fenfluramine treated group(p<0. 01 and p<0. 05). In addition,mazindol could improve sleepiness. The incidence of side effects related to gastrointestinal tract were significantly lower in the mazindol treated group. It was also found that mazindol had better effect on anti-insulin resistance and this might be valuable for obese patients with coronary heart disease.